IL316326A - Antibody that binds to VEGF-A and IL6 and methods of use - Google Patents

Antibody that binds to VEGF-A and IL6 and methods of use

Info

Publication number
IL316326A
IL316326A IL316326A IL31632624A IL316326A IL 316326 A IL316326 A IL 316326A IL 316326 A IL316326 A IL 316326A IL 31632624 A IL31632624 A IL 31632624A IL 316326 A IL316326 A IL 316326A
Authority
IL
Israel
Prior art keywords
vegf
binds
antibody
methods
Prior art date
Application number
IL316326A
Other languages
English (en)
Hebrew (he)
Inventor
Roland Beckmann
Joerg Benz
Davide Bertoldo
Faye Marie Drawnel
Derrick Feenstra
Sebastian Fenn
Stefan Frost
Marlon Hinner
Kristian Hobolt Jensen
Daniela Matscheko
Anastasia Meier
Oliver Ploettner
Janina Speck
Pamela Strassburger
Barbara Weiser
Gabriella Widmer
Original Assignee
Hoffmann La Roche
Roland Beckmann
Joerg Benz
Davide Bertoldo
Faye Marie Drawnel
Derrick Feenstra
Sebastian Fenn
Stefan Frost
Marlon Hinner
Kristian Hobolt Jensen
Daniela Matscheko
Anastasia Meier
Oliver Ploettner
Janina Speck
Pamela Strassburger
Barbara Weiser
Gabriella Widmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Roland Beckmann, Joerg Benz, Davide Bertoldo, Faye Marie Drawnel, Derrick Feenstra, Sebastian Fenn, Stefan Frost, Marlon Hinner, Kristian Hobolt Jensen, Daniela Matscheko, Anastasia Meier, Oliver Ploettner, Janina Speck, Pamela Strassburger, Barbara Weiser, Gabriella Widmer filed Critical Hoffmann La Roche
Publication of IL316326A publication Critical patent/IL316326A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL316326A 2022-05-11 2023-05-11 Antibody that binds to VEGF-A and IL6 and methods of use IL316326A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22172759 2022-05-11
PCT/EP2023/062545 WO2023217933A1 (en) 2022-05-11 2023-05-11 Antibody that binds to vegf-a and il6 and methods of use

Publications (1)

Publication Number Publication Date
IL316326A true IL316326A (en) 2024-12-01

Family

ID=81603574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316326A IL316326A (en) 2022-05-11 2023-05-11 Antibody that binds to VEGF-A and IL6 and methods of use

Country Status (16)

Country Link
US (1) US20250163139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522648A1 (cg-RX-API-DMAC10.html)
JP (2) JP7801491B2 (cg-RX-API-DMAC10.html)
KR (1) KR20250008903A (cg-RX-API-DMAC10.html)
CN (1) CN119173529A (cg-RX-API-DMAC10.html)
AR (1) AR129268A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023267952A1 (cg-RX-API-DMAC10.html)
CA (1) CA3256863A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024003373A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024015714A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240473A (cg-RX-API-DMAC10.html)
IL (1) IL316326A (cg-RX-API-DMAC10.html)
MX (1) MX2024013703A (cg-RX-API-DMAC10.html)
PE (1) PE20251283A1 (cg-RX-API-DMAC10.html)
TW (1) TW202402810A (cg-RX-API-DMAC10.html)
WO (1) WO2023217933A1 (cg-RX-API-DMAC10.html)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ATE297452T1 (de) 1998-07-23 2005-06-15 Avebe Coop Verkoop Prod Klebemittelzusammensetzung
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
WO2007104529A2 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
PT2600812T (pt) 2010-08-05 2021-11-09 Forsight Vision4 Inc Aparelho para tratar um olho
AU2011285637B2 (en) 2010-08-05 2014-10-30 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
SG195196A1 (en) 2011-05-27 2013-12-30 Dutalys Dual targeting
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Fc-수용체 기재 친화성 크로마토그래피
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
US20160302965A1 (en) 2013-12-06 2016-10-20 Forsight Vision4, Inc. Implantable therapeutic devices
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ. ホフマン-ラ ロシュ アーゲー Vegf及びpdgf-bに結合する抗体及び使用方法

Also Published As

Publication number Publication date
JP2026062918A (ja) 2026-04-10
TW202402810A (zh) 2024-01-16
PE20251283A1 (es) 2025-05-14
CA3256863A1 (en) 2023-11-16
CN119173529A (zh) 2024-12-20
CO2024015714A2 (es) 2025-04-16
WO2023217933A1 (en) 2023-11-16
CR20240473A (es) 2025-01-06
US20250163139A1 (en) 2025-05-22
EP4522648A1 (en) 2025-03-19
AU2023267952A1 (en) 2024-10-31
CL2024003373A1 (es) 2025-03-14
MX2024013703A (es) 2024-12-06
JP7801491B2 (ja) 2026-01-16
KR20250008903A (ko) 2025-01-16
AR129268A1 (es) 2024-08-07
JP2025521085A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
SMT202500208T1 (it) Composizioni anticorpali e metodi per il loro uso
IL305944A (en) Agonistic anti-IL-2R antibodies and methods of use
IL316368A (en) Anti-TL1A antibodies and methods of using them
IL319674A (en) Human anti-IL-1R3 antibody and methods of use
IL307468A (en) Bispecific antibodies targeting NKP46 and CD38 and methods of using them
HUE070287T2 (hu) Anti-PAR-2 ellenanyagok és eljárások alkalmazásukra
IL315845A (en) Anti-dectin-1 antibodies and methods of using them
IL298668B1 (en) Anti-CD200R1 antibodies and methods of using them
ZA202103643B (en) Antibody that binds to vegf and il-1beta and methods of use
IL310432A (en) Antibodies and antibody conjugates specific for nectin-4 and methods of using them
IL316918A (en) Chimeric antigen receptor and IL-18 receptor compositions and methods of using them
IL316065A (en) Anti-CD28 antibodies and methods of using them
IL319528A (en) Trivalent and trispecific antibody structures and methods of using them
IL318694A (en) Antibodies against CCR8 and methods of using them
IL317690A (en) Anti-GPNMB antibodies and methods of using them
IL313265A (en) Antagonistic antibodies against NPR1 and methods of using them
CA3256863A1 (en) ANTIBODIES BINDING TO VEGF-A AND IL6 AND METHODS OF USE
IL300104A (en) Antibody specific for mucin-1 and methods of using it
IL308260A (en) Antibodies against Tigit and methods of using them
IL316700A (en) ANTI-BMP9 antibodies and methods of using them
IL318129A (en) Multivalent and bispecific antibody structures and methods of using them
IL310551A (en) Monoclonal antibodies specific for OSMR and methods of using them
IL325886A (en) Cd276 antibody and methods of use thereof
IL317319A (en) Antibody compounds and methods of using them